Open an account

IDEAYA Biosciences

IDYA · NASDAQ

$35.36+$1.55 (+4.58%)TodayMarket closed ·
Prev close $33.81

About IDYA

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Employees
145
Headquarters
South San Francisco, California
Listed
May 23, 2019
Sector
Health Care
Industry
Biotechnology
Website
ideayabio.com

IDYA key statistics

Market cap
3.41B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
849.48K
Volume
962.07K
Open price
$33.93
High today
$35.63
Low today
$33.74
52 Week high
$42.68
52 Week low
$26.81

IDEAYA Biosciences (IDYA) at a glance

IDEAYA Biosciences (IDYA) last traded at $35.36, with a market cap of 3.41B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $33.74 and $35.63. The current price is 4.8% above the day's low and 0.8% below its high.

Volume so far is 962.07K shares, in line with the average of 849.48K shares a day.

Over the past year IDEAYA Biosciences has ranged from $26.81 to $42.68, and now sits 54% of the way up that range.

IDEAYA Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.22 per share against an estimate of -$1.11.

The average analyst price target is $53.81, 52.2% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

93%of 14 analyst ratings say Buy
  • Buy92.9%
  • Hold7.1%
  • Sell0.0%
Price target · 15 analystsAvg $53.81
Low
$31.31
Now
$35.36
High
$68.25

IDYA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 117.1% on average.

  1. Q3 FY24: reported -$0.60 per share against an estimate of -$0.6469
  2. Q4 FY24: reported -$1.49 per share against an estimate of -$0.6526
  3. Q1 FY25: reported -$0.82 per share against an estimate of -$0.6747
  4. Q2 FY25: reported -$0.88 per share against an estimate of -$0.805
  5. Q3 FY25: reported $1.33 per share against an estimate of -$0.5557
  6. Q4 FY25: reported -$0.94 per share against an estimate of -$0.9869
  7. Q1 FY26: reported -$1.11 per share against an estimate of -$1.01
  8. Q2 FY26: reported -$1.22 per share against an estimate of -$1.11

IDYA news

  • Press releasePRNewswire

    IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

  • Press releasePRNewswire

    IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

  • Press releasePRNewswire

    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

  • Press releasePRNewswire

    IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

  • Press releasePRNewswire

    IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

  • Press releasePRNewswire

    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

Similar companies

Companies in the same industry as IDEAYA Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.